Q BioMed Inc. (QBIO)

0.0002 0.0000 (0.00%) At close: 02:32PM EDT

Q BioMed Inc.

366 Madison Avenue
3rd Floor
New York, NY 10017
United States
212 588 0022
https://www.qbiomed.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Denis D. Corin	Chairman, CEO & President	300k	N/A	1973
Mr. William S. Rosenstadt	Chief Legal Officer, General Counsel & Director	300k	N/A	1968

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

Corporate governance

Q BioMed Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.